Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US, Canada Setting Trend For Global Cybersecurity Guidance

Executive Summary

A draft IMDRF guidance released this month aims to set the trend for how regulators around the world oversee cybersecurity of medical devices. According to experts, the document also foreshadows what sponsors can expect from the US FDA in areas such as developing a software bill of materials, as the agency updates its own cybersecurity guidances.

You may also be interested in...



MDIC Cybersecurity Benchmarking Maturity Report: An ‘Honest Reflection’ Of The Industry

In an event hosted by the Medical Device Innovation Consortium, cybersecurity experts discussed a benchmark report on the state of cybersecurity in the device industry. The director of digital health product security policy at Medtronic previewed the updated Joint Security Plan.

A Deep Dive With US FDA’s Suzanne Schwartz: COVID-19, Cybersecurity, Device Shortages, And More

As head of the device center’s emergency response program, Schwartz oversees a broad range of issues, from medical device shortages to cybersecurity vulnerabilities. We talk to her in this Medtech Insight profile.

International Regulators Issue Final Cybersecurity Guidance

A final IMDRF guidance on medical device cybersecurity reinforced US and Canadian regulatory thinking on issues such as a total product life cycle approach, shared responsibility and creating a software bill of materials.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel